Complix is a biopharmaceutical company developing a pipeline of transformative Alphabody based therapeutics against a number of cutting-edge and challenging disease targets that play an important role in viral diseases, oncology and autoimmunity
Complix is backed by a syndicate of experienced life sciences investors. Since its founding in 2008, Complix has raised over €30 million in equity financing (approximately US$35 million).
The most recent financing in 2020 was co-led by LRM (Belgium), Vesalius Biocapital (Luxembourg) and PMV (Belgium). Gemma Frisius Fund, LRD, TrustCapital and management also participated in this round.
Complix Cell Penetrating Alphabodies
A new revolutionary class of therapeutics targeting intracellular targets